IsoPSA
Accurate. Simple. Proven.
Improve risk assessment to better inform your prostate biopsy decision‑making.
Dr. Mark Stovsky on IsoPSA's Longitudinal Performance & Utility in Patient Monitoring
Case Study: IsoPSA Reveals csPCa in a PI-RADS 2 Lesion
Case Study: Monitoring Prostate Cancer Progression with IsoPSA
IsoPSA in Practice: Guiding Biopsy Decisions and Monitoring Patients
Dr. Jason Hafron Breaks Down the Data on IsoPSA’s Longitudinal Performance
Insights from Dr. Arpeet Shah on the Clinical Impact of IsoPSA
Case Study: Undergoing Active Surveillance
Case Study: Identifying csPCa with normal mpMRI
Case Study: Borderline Biopsy
Case Study: Active Surveillance
Case Study: African American Male Referred by PCP
Case Study: Convincing PSA Skeptics
AUA 2024: Dr. Aaron Berger - Breakthroughs in Prostate Cancer Risk Assessment